

ADX' PRESENTATIONS AND POSTERS

FORMAT	TITLE	PRESENTER
Monday July 17		
Poster P2-939	Performance of optimized prototype LUMIPULSE G immunoassays for plasma pTau181 and pTau217	Charlotte Lambrechts
Poster P2-954	Performance testing of a novel GFAP ELISA for CSF and blood based matrices	Laure De Waele
Presentation 2:15-3:30pm Hall 10	Differential expression of synaptic biomarkers in CSF differentiates behavioural variant of frontotemporal dementia from primary psychiatric disorders and Alzheimer's disease. <i>Session: Fluid biomarkers of frontotemporal dementia, Lewy body disease, and TDP-43 proteinopathies</i>	Shreyasee Das (MIRIADE)
Tuesday July 18		
Presentation 08:00-08:45am Hall 3	Two novel β-synuclein specific assays for the detection of Alzheimer's disease <i>Lightning Presentation Round: Biomarkers</i>	Sherif Bayoumy (MIRIADE)
Wednesday July 19		
Poster P4-281	Performance of plasma pTau181 and pTau217 measured with fully automated LUMIPULSE G prototype immunoassays	Jeroen Vanbrabant

CONTRIBUTIONS TO RESEARCH: ADX INSIDE

FORMAT	TITLE	PRESENTER
Sunday July 16		
Poster P1-342	Plasma biomarkers rates of change across the preclinical stage of Alzheimer's disease: a longitudinal study	A. González Escalante Barcelonaβeta Brain Research Center
Monday July 17		
Poster P2-894	Optimizing plasma biomarker combinations for the detection of amyloid pathology in cognitively unimpaired individuals	J. Contador Barcelonaβeta Brain Research Center
Poster P2-960	The detection of phosphorylated tau in tear fluid	G. Di Molfetta University of Gothenburg



Poster P2-978	Blood-based SNAP-25 and VAMP-2 in Alzheimer's disease; relation to cognition, atrophy and synaptic density.	M. Sauer University of Gothenburg
Poster P2-272	Plasma SNAP-25 as a potential Alzheimer's disease biomarker	F. Ribaldi Geneva University Hospitals
Tuesday July 18		
Poster P3-224	Profiling amyloid-β peptides as diagnostic biomarkers for cerebral amyloid angiopathy	E. van den Berg Radboud University Medical Center
Poster P3-277	Preliminary performance overview of the Lumipulse G pTau 217 Plasma RUO assay	M. Vandijck Fujirebio Europe
Presentation – 2:25-2:35pm Hall 2	Plasma ALZpath pTau217 for the identification of amyloid and tau positivity <i>Session: Blood-based biomarkers in Alzheimer's disease</i>	N. Asthon University of Gothenburg
Wednesday July 19		
Poster P4-261	Plasma phosphorylated tau 217 levels are highly stable under common pre-analytical sample handling procedures	M. Gouda Amsterdam UMC
Poster P4-369	Exploring biomarker profiles of the cognitively unimpaired individuals in early tau PET Braak stage	Nicholas Ashton University of Gothenburg
Poster P4-310	Cross-sectional investigation of synaptic markers Neurogranin and BACE1 in CSF from the AIBL study	C. Fowler Florey University

